Clinical trials: Graft Rejection
Lung Transplant Rejection
Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy
This study will sample and analyze volatile organic compounds (VOCs) from participants considered to be at risk for developing rejection following lung transplant by using infrared spectroscopy.
- Trial name
- NCT06309628
- Testing
- Breathe sample
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Paragonix Technologies
Kidney Transplant Rejection, End Stage Renal Disease
Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)
This long-term follow-up study is being conducted to collect long-term (up to 15 years post-infusion) safety and tolerability data from subjects enrolled in studies evaluating TX200-TR101.
- Trial name
- NCT05987527
- Testing
- Blood sample
- Where
- 5 sites in Belgium, Netherlands and 1 more
- Volunteers
- 11 people
- Sponsor
- Sangamo Therapeutics
Kidney Transplant Failure and Rejection
BIOtechnology Applied to Renal TRansplantation With IMmunobiogram
Immunobiogram (IMBG) is a novel in vitro diagnostic bioassay developed by Biohope Scientific Solutions for Human Health SL, that allows to measure the pharmacodynamic response to individual immunosuppressive drugs in patients…
- Trial name
- BIOTRAIM (NCT05816486)
- Testing
- Immunobiogram
- Where
- 15 sites in Brazil, France and 3 more
- Volunteers
- 443 people
- Sponsor
- Biohope Scientific Solutions for Human Health, S.L.
Kidney Transplant Rejection
Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in patients undergoing kidney transplantation.
- Trial name
- NCT05983770
- Testing
- AT-1501, Tacrolimus
- Where
- 43 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Eledon Pharmaceuticals
Infection in Solid Organ Transplant Recipients
T-SPOT.CMV and T-SPOT.PRT Diagnostic Assays
The T-SPOT assay quantifies the number of peripheral blood interferon-γ producing effector T cells [spot forming cells/million peripheral blood mononuclear cells - PBMC)].
- Trial name
- PROTECT (NCT02382211)
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 600 people
- Sponsor
- Oxford Immunotec
Graft Rejection, Kidney Failure
Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients
The purpose of the study is to determine the effect of conversion from calcineurin inhibitor based therapy to Rapamune based therapy in patients with mild to moderate renal insufficiency.
- Conditions
- Graft Rejection, Kidney Failure, Kidney Transplantation
- Trial name
- NCT00273871
- Testing
- Cyclosporin or tacrolimus
- Volunteers
- 190 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Autoimmune Diseases, Inflammation
Prospective Study of White Blood Cells
The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.
- Conditions
- Autoimmune Diseases, Inflammation, Rejection; Transplant, Liver
- Trial name
- NCT04838171
- Testing
- White blood cell and blood collection
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Quell Therapeutics Limited
Chronic Kidney Insufficiency
Non-interventional-study With Tacrolimus Sandoz© Capsules for Prophylaxis of Renal Graft Rejection
This non-interventional study intends to collect epidemiological data in patients with stable kidney function after renal transplantation, who receive Tacrolimus Sandoz© according to the approved indication.
- Trial name
- NCT01353417
- Testing
- In this observational study no study specific intervention is planned
- Where
- Austria
- Volunteers
- 102 people
- Sponsor
- Sandoz
Acute Rejection of Cardiac Transplant
Non-invasive Test for Acute Rejection Identification in Heart Transplanted Patients
Aim of the study is to test INNOGRAFT Heart Suite in a clinical setting, using a previously collected set of plasma samples from patients who underwent heart transplant and routinely or symptoms-based surveillance during the…
- Trial name
- INNOGRAFTRS001 (NCT04274712)
- Testing
- INNOGRAFT Heart Suite
- Where
- Italy
- Volunteers
- 72 people
- Sponsor
- Myway Gentics Srl
Kidney Transplant Rejection
Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection
Global, non-randomized, observational study for the validation of Verici Dx genomic tests to predict risk of kidney clinical and subclinical acute rejection, and chronic allograft damage or interstitial fibrosis / tubular atrophy…
- Trial name
- NCT04727788
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 550 people
- Sponsor
- Verici Dx
Antibody-Mediated Graft Rejection
Cell-based Assays for Antibody-mediated Transplant Rejection
Goal: The goal of this study is to validate blood tests, which can detect antibody-mediated rejection (ABMR) after renal transplantation.
- Trial name
- NCT03916822
- Testing
- Alloantigen-specific B-cells
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Plexision
Kidney Transplantation
Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant
The safety and efficacy of FTY720 is being evaluated in patients who receive a kidney transplant.
- Trial name
- NCT00099801
- Testing
- FTY720
- Sponsor
- Novartis Pharmaceuticals
Graft Rejection, Kidney Transplant
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
This study will look at the effect on long-term kidney function using tacrolimus right after a transplant and then switching to sirolimus at 3 to 5 months after the transplant.
- Conditions
- Graft Rejection, Kidney Transplant, Renal Allograft Recipients, Renal Transplant
- Trial name
- NCT00895583
- Testing
- Tacrolimus, Sirolimus
- Where
- 44 sites in United States, Argentina and 5 more
- Volunteers
- 254 people
- Sponsor
- Pfizer
Liver Transplant Rejection
TRU-IMMUNO: Optimizing Liver Immunosuppression
This is a prospective, multi-center, randomized study. The primary objective is to evaluate the feasibility and utility of TruGraf/TRAC Liver testing used in addition to standard of care measures of liver dysfunction to guide…
- Trial name
- NCT05335551
- Testing
- Patients monitored with TruGraf and TRAC Liver testing
- Volunteers
- 130 people
- Sponsor
- Transplant Genomics, Inc.
Kidney Transplantation
Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients
The purpose of this study is to compare the safety and efficacy of different induction agents (alemtuzumab, basiliximab or rabbit anti-thymocyte globulin) in renal transplant recipients treated with tacrolimus, mycophenolate…
- Trial name
- INTAC (NCT00113269)
- Testing
- basiliximab, rabbit anti-thymocyte globulin, tacrolimus
- Where
- 29 sites in United States
- Volunteers
- 501 people
- Sponsor
- Astellas Pharma Inc
Graft Rejection
A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection
The purpose of this research study is to evaluate the safety, effect, and pharmacology of C1 Esterase Inhibitor (human) in kidney transplant patients with acute Antibody-Mediated Rejection (AMR).
- Trial name
- NCT01147302
- Testing
- C1 Esterase Inhibitor (Human)
- Where
- 5 sites in United States, Germany
- Volunteers
- 18 people
- Sponsor
- Shire
Heart Transplant Rejection
Heartsbreath Test for Heart Transplant Rejection
The purpose of this study is to demonstrate and validate a breath test for detection of biomarkers of heart transplant rejection (Grade 2R heart transplant).
- Trial name
- Heartsbreath (NCT01397812)
- Testing
- BreathScanner 1.0, BreathLink
- Where
- 5 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Menssana Research, Inc.
Prevention of Graft Rejection After Organ Transplantation
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects
This is a single-center, double-blind, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-3032 in healthy adults.
- Trial name
- NCT06090799
- Testing
- SHR-3032
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Kidney Transplantation
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation
In patients who receive an organ transplant, their body considers this organ as foreign and attempts to destroy it. This is called rejection.
- Trial name
- NCT00098735
- Testing
- FTY720
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Failure, Kidney Diseases
Study Evaluating Sirolimus in the Treatment of Kidney Transplant
The aim of this study is to test whether withdrawal of calcineurin inhibitors, followed by treatment with sirolimus, may improve renal function in renal transplant recipients with chronic allograft nephropathy.
- Trial name
- NCT00282217
- Testing
- Sirolimus
- Where
- 13 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer